Advances in prostate cancer immunotherapy.
Metastatic prostate cancer remains incurable. Harnessing the body's own immune system to control or eradicate tumours has long been an attractive concept. Only recently has the field of tumour immunology provided the basic science behind the mechanisms of tumour genesis, molecular basis of the recognition of tumour associated antigens and the interactions of the antigen-presenting cells with effector cells. This research has been translated into numerous clinical immunotherapy strategies, which have reached the oncology clinic and which should provide options for our patients.
Havranek
E G
EG
Department of Urology, St. George's Hospital Medical School, London SW17 0RE, UK.
Whelan
M A
MA
Greenhalgh
R
R
Dalgleish
A G
AG
Pandha
H
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D015774:Ganciclovir / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D051381:Rats; D019444:Vaccines, DNA / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D016207:Cytokines; D019444:Vaccines, DNA; D017430:Prostate-Specific Antigen; D015774:Ganciclovir